Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome
暂无分享,去创建一个
[1] F. W. Denny,et al. Prevention of rheumatic fever; treatment of the preceding streptococcic infection. , 1950, Journal of the American Medical Association.
[2] R. Knodell,et al. EFFICACY OF PROPHYLACTIC GAMMA-GLOBULIN IN PREVENTING NON-A, NON-B POST-TRANSFUSION HEPATITIS , 1976, The Lancet.
[3] E. Schiff,et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. , 1977, Gastroenterology.
[4] R. Purcell,et al. TRANSMISSIBLE AGENT IN NON-A, NON-B HEPATITIS , 1978, The Lancet.
[5] L. Seeff,et al. TRANSMISSION OF NON-A, NON-B HEPATITIS FROM MAN TO CHIMPANZEE , 1978, The Lancet.
[6] R. Purcell,et al. Non-A, non-B hepatitis. , 1976, Annual review of medicine.
[7] R. Kahn,et al. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. , 1981, The New England journal of medicine.
[8] J. Dienstag. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features , 1983 .
[9] R. Purcell,et al. Primate Animal Models and Titered Inocula for the Study of Human Hepatitis A, Hepatitis B, and Non‐A, Non‐B Hepatitis , 1983, Journal of medical primatology.
[10] K. Geisinger,et al. Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. , 1984, Annals of internal medicine.
[11] T. Shikata,et al. [Non-A, non-B viral hepatitis]. , 1985, Nihon rinsho. Japanese journal of clinical medicine.
[12] C. Cunningham-Rundles,et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. , 1988, The American journal of medicine.
[13] H. Alter. Chronic Consequences of Non-A, Non-B Hepatitis , 1989 .
[14] M. Houghton,et al. PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN ITALIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA , 1989, The Lancet.
[15] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[16] J. Bruix,et al. PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN SPANISH PATIENTS WITH HEPATOCELLULAR CARCINOMA AND HEPATIC CIRRHOSIS , 1989, The Lancet.
[17] E. Schiff,et al. Hepatitis C–associated hepatocellular carcinoma , 1990, Hepatology.
[18] P. Coursaget,et al. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. , 1990, Journal of the National Cancer Institute.
[19] R. Purcell,et al. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.
[20] M. Houghton,et al. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma , 1990, The Lancet.
[21] M. Houghton,et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan , 1991 .
[22] K. Ishak,et al. Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis , 1991, Hepatology.
[23] L. Seeff. Hepatitis C from a needlestick injury. , 1991, Annals of internal medicine.
[24] J. Hoofnagle,et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. , 1991, The American journal of gastroenterology.
[25] F. Iber,et al. Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .
[26] R. Miller,et al. Lack of protective immunity against reinfection with hepatitis C virus. , 1993, Science.
[27] A. Alberti,et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1993, Journal of hepatology.
[28] E. Schiff,et al. Viral pathogenesis of hepatocellular carcinoma in the United States , 1993, Hepatology.
[29] Richard E. Sampliner,et al. The Natural History of Community-Acquired Hepatitis C in the United States , 1993 .
[30] S. Gordon,et al. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. Intravenous drug use , 1993, Hepatology.
[31] J. Goedert,et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.
[32] R. Koretz,et al. Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade , 1993, Annals of Internal Medicine.
[33] O. Weiland,et al. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. , 2008, Liver.
[34] C. Sabin,et al. The progression of HCV‐associated liver disease in a cohort of haemophilic patients , 1994, British journal of haematology.
[35] S. Nagataki,et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses , 1994, Cancer.
[36] R. Purcell,et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children , 1994, The Lancet.
[37] R. Purcell,et al. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses , 1994, Journal of virology.
[38] L. Corey,et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. , 1994, The Journal of infectious diseases.
[39] Kenichi Kobayashi,et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease , 1994, Journal of medical virology.
[40] D. Trichopoulos,et al. A case‐control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma , 1995, International journal of cancer.
[41] H. Conjeevaram,et al. Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features , 1995, Annals of Internal Medicine.
[42] M. Tong,et al. Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.
[43] A. Hughes,et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[44] M. Houghton,et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[45] H. Okamoto,et al. HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C , 1996, Journal of medical virology.
[46] R. Müller. The natural history of hepatitis C: clinical experiences. , 1996, Journal of hepatology.
[47] A. Czaja,et al. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. , 1996, Journal of hepatology.
[48] J. Ludwig,et al. The long‐term pathological evolution of chronic hepatitis C , 1996, Hepatology.
[49] J W Shih,et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. , 1996, The New England journal of medicine.
[50] R. Wood. HEPATITIS C INFECTION IN PATIENTS WITH PRIMARY HYPOGAMMAGLOBULINEMIA AFTER TREATMENT WITH CONTAMINATED IMMUNE GLOBULIN , 1996, Pediatrics.
[51] A. Bhalla,et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.
[52] J. Hoofnagle,et al. Hepatitis C in asymptomatic blood donors , 1997, Hepatology.
[53] T. Wright,et al. Hepatitis C infection in transplantation. , 1997, Clinics in liver disease.
[54] A. Alberti,et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. , 1997, Blood.
[55] P. Bedossa,et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.
[56] G. Davis,et al. Factors predictive of a beneficial response to therapy of hepatitis C , 1997, Hepatology.
[57] S. Darby,et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C , 1997, The Lancet.
[58] J. Emparanza,et al. [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.
[59] D. Häussinger,et al. Prognosis of chronic hepatitis c: Results of a large, prospective cohort study , 1998, Hepatology.
[60] M. Fernández-Bermejo,et al. Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adult patients , 1998, Hepatology.
[61] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[62] T. Layden,et al. Impact of alcohol on the histological and clinical progression of Hepatitis C infection , 1998, Hepatology.
[63] G. Ostapowicz,et al. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection , 1998, Hepatology.
[64] J. M. Calvo Romero,et al. Gastric adenocarcinoma and kidney transplantation , 1998 .
[65] G. Corrao,et al. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. , 1998, Hepatology.
[66] Yasuyuki Arakawa,et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.
[67] F. Chisari,et al. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence , 1999, Hepatology.
[68] Mark Thursz,et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus , 1999, The Lancet.
[69] E. Kenny‐Walsh. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. , 1999, The New England journal of medicine.
[70] C. Tiribelli,et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study , 1999, Gut.
[71] Inda,et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.
[72] D. Vlahov,et al. Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection , 1999, Hepatology.
[73] M. Goldman. Determinants of outcome of compensated hepatitis C virus related cirrhosis , 1999 .
[74] L. Seeff,et al. 45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults , 2000, Annals of Internal Medicine.
[75] H J Alter,et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.
[76] J. Hess,et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. , 1999, Clinical pediatrics.
[77] P. Arbuthnot,et al. Hepatitis B virus and hepatocellular carcinoma , 2001, International journal of experimental pathology.